A Phase 3 interventional study of DR-104 in Emergency Contraception, sponsored by Duramed Research. Completed at 5 sites in United States. Open to female participants aged 11 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-18.
Sponsored by Duramed Research (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a non-comparative case series study to assess the ability of females 11-16 years of age, inclusive, who are requesting emergency contraception (EC) to use the study product, DR-104 (Plan B® 1.5), appropriately and safely without provider counseling.
To simulate an over-the-counter (OTC) setting, each potential subject was expected to read the label text on the outside of the study package and determine whether and how to use the study product without provider direction or assistance. The study product, Plan B® 1.5, was to be dispensed only to those subjects who appropriately self-selected and indicated that they wanted to participate in the study and receive study product. Subjects could also appropriately self-select not to use the study product.
Follow-up contact was to be conducted at approximately one, four, and eight weeks following the date the subject was dispensed study product. At these contacts, subjects answered questions regarding product use, health problems since last contact, and pregnancy status. Subjects were not to be permitted to enroll more than once in this Actual Use Study, however to assess repeat use of emergency contraceptives (EC) (use in addition to the study product) subjects were also queried at the one-, four-, and eight-week follow-up contacts regarding use of additional EC.
Duramed Research is the lead sponsor of 24 studies on the registry; none are open to participants now.
First submitted before Duramed Research became part of Teva Pharmaceutical Industries, Ltd..
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One tablet for emergency contraception
Drug: DR-104
One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.
Also known as: Plan B® 1.5, Plan B One-Step®, levonorgestrel
Percentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions
The percentage of participants who appropriately self-selected Plan B® 1.5 at the Screening/Enrollment Visit after reading the product label. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-diagnose the condition and that treatment with the product is appropriate for them.
Time frame: Day 1
Percentage of Participants Who Correctly Used DR-104 When Dispensed Under Simulated OTC Conditions
The percentage of participants who having appropriately self-selected and been dispensed Plan B® 1.5, correctly used it according to product labeling. Correct use was considered to have occurred if participants reported at the Week 1 follow-up contact that she took Plan B® 1.5 within 72 hours following unprotected sexual intercourse. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-treat with the product according to the product instructions.
Time frame: Week 1
Participants With Treatment-Emergent Adverse Events (TEAE)
Treatment-emergent adverse events included adverse events reported during the protocol-specified following up contacts at weeks 1, 4 and 8 or at any other participant contact for participants who took study drug.
Time frame: Day 1 to week 8
Participants Summarized by Repeat Use of Emergency Contraception (EC)
As each participant dispensed Plan B® 1.5 was only given one tablet, repeat use of emergency contraception (EC) indicates use of an EC product other than the study product. Categories reflect the number of repeat uses.
Time frame: up to week 8
| Milestone | DR-104 |
|---|---|
| Started | 343 |
| Dispensed product | 307 |
| Safety population | 299 |
| Used product | 297 |
| Completed | 277 |
| Not completed | 66 |
| Withdrew: Inappropriate self-selection | 34 |
| Withdrew: Dispensed but did not use product | 12 |
| Withdrew: Did not complete all 3 follow-up visits | 20 |
The percentage of participants who appropriately self-selected Plan B® 1.5 at the Screening/Enrollment Visit after reading the product label. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-diagnose the condition and that treatment with the product is appropriate for them.
| percentage of participants | DR-104 |
|---|---|
| Percentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions | 90.1 (NA to 86.4) |
The percentage of participants who having appropriately self-selected and been dispensed Plan B® 1.5, correctly used it according to product labeling. Correct use was considered to have occurred if participants reported at the Week 1 follow-up contact that she took Plan B® 1.5 within 72 hours following unprotected sexual intercourse. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-treat with the product according to the product instructions.
| percentage of treated participants | DR-104 |
|---|---|
| Percentage of Participants Who Correctly Used DR-104 When Dispensed Under Simulated OTC Conditions | 88.6 (NA to 84.4) |
Treatment-emergent adverse events included adverse events reported during the protocol-specified following up contacts at weeks 1, 4 and 8 or at any other participant contact for participants who took study drug.
| participants | DR-104 |
|---|---|
| At least one TEAE | 43 |
| Withdrawn from study due to an AE | 0 |
| At least one SAE | 1 |
As each participant dispensed Plan B® 1.5 was only given one tablet, repeat use of emergency contraception (EC) indicates use of an EC product other than the study product. Categories reflect the number of repeat uses.
| participants | DR-104 |
|---|---|
| Repeat uses: 0 | 251 |
| Repeat uses: 1 | 38 |
| Repeat uses: 2 | 16 |
| Repeat uses: 3 | 2 |
Collected over Day 1 to week 8. Unresolved AEs and pregnancies were followed until resolved.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DR-104 | — | 1/299 (0.3%) | 0/299 (0%) |
| Event | DR-104 |
|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/299 |
| Age, Categorical(Participants) | DR-104 |
|---|---|
| <=18 years | 343 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Customized(participants) | DR-104 |
|---|---|
| 11-13 years old | 3 |
| 14 years old | 35 |
| 15 years old | 100 |
| 16 years old | 140 |
| 17 years old | 65 |
| Sex: Female, Male(Participants) | DR-104 |
|---|---|
| Female | 343 |
| Male | 0 |
| Race/Ethnicity, Customized(participants) | DR-104 |
|---|---|
| Latina | 147 |
| African-American | 48 |
| Multiracial | 23 |
| White | 39 |
| Asian/Pacific Islander | 68 |
| Native American/Alaskan Native | 1 |
| Other | 17 |
| Ethnic Latina/Hispanic(participants) | DR-104 |
|---|---|
| No answer | 17 |
| Yes | 169 |
| No | 151 |
| Don't know | 6 |
The record gives a start of Oct 2008, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levonorgestrel